RxDoctor Payments Data

Daniel Hammer, MD

Ophthalmology · Cincinnati, OHNPI 1346575479

Payments from drug & device makers

$8,698in general payments, 2019–2025

Across 171 payments — averaging $50.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Haag-streit USA, Inc.$3K
  • AbbVie$1K
  • Axogen$1K
  • Alcon$1K
  • Aerie Pharmaceuticals, Inc.$415
  • Bausch & Lomb Americas Inc.$297
  • plus $1K from 18 others

What the payments were for

  • Consulting fees$3,00034%
  • Travel & lodging$1,00212%
  • Food & beverage$4,61753%
  • Education$801%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,698 in reported general payments places this provider in the 85th percentile of 640 ophthalmology providers in Ohio.

See all ophthalmology providers in Ohio

Medicare billing

Part B allowed, 2024
$237,186
Medicare patients
550
Services billed
1,951

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost331$159,881
RhopressaNetarsudil Mesylate120$59,117
CombiganBrimonidine Tartrate/Timolol88$32,973
Alphagan PBrimonidine Tartrate46$24,765
RocklatanNetarsudil Mesylat/Latanoprost47$23,433
XiidraLifitegrast18$19,195
VyzultaLatanoprostene Bunod33$17,732
SimbrinzaBrinzolamide/Brimonidine Tart53$17,649
Prednisolone Acetate411$11,615
Latanoprost1,132$10,462
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat759$8,990
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol57$8,429
Brinzolamide74$8,188
Travoprost43$7,121
Brimonidine Tartrate372$6,950

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan, Alphagan P$1,480$217,619465 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$415$82,550167 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$297$36,92651 claims
AlconSimbrinza$1,062$17,64953 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate$71$7,16730 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 640 ophthalmology providers in Ohio.

Other ophthalmology in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →